{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T18:46:21Z","timestamp":1794336381031,"version":"4.9.0"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:00Z","timestamp":1750636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:00Z","timestamp":1750636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Aging"],"DOI":"10.1038\/s43587-025-00904-3","type":"journal-article","created":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T05:02:01Z","timestamp":1750654921000},"page":"1601-1618","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Comprehensive evaluation of plasma tau biomarkers for detecting and monitoring Alzheimer\u2019s disease in a multicenter and multiethnic aging population"],"prefix":"10.1038","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2925-1738","authenticated-orcid":false,"given":"Guoyu","family":"Lan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengjie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7897-9456","authenticated-orcid":false,"given":"Fernando","family":"Gonzalez-Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laihong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7793-224X","authenticated-orcid":false,"given":"Anqi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binyin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxing","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuhui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7135-2631","authenticated-orcid":false,"given":"Pan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieyin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengbo","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9321-3632","authenticated-orcid":false,"given":"Xin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linsen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liemin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanxun","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinlu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengcheng","family":"Ran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9883-1616","authenticated-orcid":false,"given":"Kun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihui","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1890-4193","authenticated-orcid":false,"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2667-281X","authenticated-orcid":false,"given":"Fang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2982-0865","authenticated-orcid":false,"given":"Tengfei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,23]]},"reference":[{"key":"904_CR1","doi-asserted-by":"crossref","unstructured":"2024 Alzheimer\u2019s disease facts and figures. Alzheimer\u2019s Dement. 20, 3708\u20133821 (2024).","DOI":"10.1002\/alz.13809"},{"key":"904_CR2","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/S1474-4422(19)30290-X","volume":"19","author":"L Jia","year":"2020","unstructured":"Jia, L. et al. Dementia in China: epidemiology, clinical management, and research advances. Lancet Neurol. 19, 81\u201392 (2020).","journal-title":"Lancet Neurol."},{"key":"904_CR3","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/s43587-023-00403-3","volume":"3","author":"O Hansson","year":"2023","unstructured":"Hansson, O., Blennow, K., Zetterberg, H. & Dage, J. Blood biomarkers for Alzheimer\u2019s disease in clinical practice and trials. Nat. Aging 3, 506\u2013519 (2023).","journal-title":"Nat. Aging"},{"key":"904_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck, C. H. et al. Lecanemab in early Alzheimer\u2019s disease. N. Engl. J. Med. 388, 9\u201321 (2023).","journal-title":"N. Engl. J. Med."},{"key":"904_CR5","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims, J. R. et al. Donanemab in early symptomatic alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 330, 512\u2013527 (2023).","journal-title":"JAMA"},{"key":"904_CR6","doi-asserted-by":"publisher","unstructured":"Jack, C. R. et al. Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup. Alzheimer\u2019s Dement. https:\/\/doi.org\/10.1002\/alz.13859 (2024).","DOI":"10.1002\/alz.13859"},{"key":"904_CR7","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nature25456","volume":"554","author":"A Nakamura","year":"2018","unstructured":"Nakamura, A. et al. High performance plasma amyloid-\u03b2 biomarkers for Alzheimer\u2019s disease. Nature 554, 249\u2013254 (2018).","journal-title":"Nature"},{"key":"904_CR8","doi-asserted-by":"publisher","first-page":"E1647","DOI":"10.1212\/WNL.0000000000008081","volume":"93","author":"SE Schindler","year":"2019","unstructured":"Schindler, S. E. et al. High-precision plasma \u03b2-amyloid 42\/40 predicts current and future brain amyloidosis. Neurology 93, E1647\u2013E1659 (2019).","journal-title":"Neurology"},{"key":"904_CR9","doi-asserted-by":"publisher","first-page":"e209205","DOI":"10.1212\/WNL.0000000000209205","volume":"102","author":"Y Cai","year":"2024","unstructured":"Cai, Y. et al. Association of \u03b2-amyloid, microglial activation, cortical thickness, and metabolism in older adults without dementia. Neurology 102, e209205 (2024).","journal-title":"Neurology"},{"key":"904_CR10","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/s41582-022-00665-2","volume":"18","author":"TK Karikari","year":"2022","unstructured":"Karikari, T. K. et al. Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility. Nat. Rev. Neurol. 18, 400\u2013418 (2022).","journal-title":"Nat. Rev. Neurol."},{"key":"904_CR11","doi-asserted-by":"publisher","unstructured":"Rodriguez, L. et al. Plasma N-terminal containing tau fragments (NTA-tau): a biomarker of tau deposition in Alzheimer\u2019s disease. Mol. Neurodegener. https:\/\/doi.org\/10.1186\/s13024-024-00707-x (2024).","DOI":"10.1186\/s13024-024-00707-x"},{"key":"904_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23620-z","volume":"12","author":"NJ Ashton","year":"2021","unstructured":"Ashton, N. J. et al. A multicentre validation study of the diagnostic value of plasma neurofilament light. Nat. Commun. 12, 3400 (2021).","journal-title":"Nat. Commun."},{"key":"904_CR13","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1001\/jamaneurol.2016.6117","volume":"74","author":"N Mattsson","year":"2017","unstructured":"Mattsson, N. et al. Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. JAMA Neurol. 74, 557\u2013566 (2017).","journal-title":"JAMA Neurol."},{"key":"904_CR14","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1093\/brain\/awae035","volume":"147","author":"P S\u00e1nchez-Juan","year":"2024","unstructured":"S\u00e1nchez-Juan, P. et al. Serum GFAP levels correlate with astrocyte reactivity, post-mortem brain atrophy and neurofibrillary tangles. Brain 147, 1667\u20131679 (2024).","journal-title":"Brain"},{"key":"904_CR15","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1038\/s41591-023-02380-x","volume":"29","author":"B Bellaver","year":"2023","unstructured":"Bellaver, B. et al. Astrocyte reactivity influences amyloid-\u03b2 effects on tau pathology in preclinical Alzheimer\u2019s disease. Nat. Med. 29, 1775\u20131781 (2023).","journal-title":"Nat. Med."},{"key":"904_CR16","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13024-024-00750-8","volume":"19","author":"T Guo","year":"2024","unstructured":"Guo, T. et al. Astrocyte reactivity is associated with tau tangle load and cortical thinning in Alzheimer\u2019s disease. Mol. Neurodegener. 19, 58 (2024).","journal-title":"Mol. Neurodegener."},{"key":"904_CR17","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1093\/brain\/awac333","volume":"146","author":"S Janelidze","year":"2023","unstructured":"Janelidze, S. et al. Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer\u2019s disease. Brain 146, 1592\u20131601 (2023).","journal-title":"Brain"},{"key":"904_CR18","doi-asserted-by":"publisher","unstructured":"Schindler, S. E. et al. Head-to-head comparison of leading blood tests for Alzheimer\u2019s disease pathology. Alzheimer\u2019s Dement. https:\/\/doi.org\/10.1002\/alz.14315 (2024).","DOI":"10.1002\/alz.14315"},{"key":"904_CR19","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jama.2020.12134","volume":"324","author":"S Palmqvist","year":"2020","unstructured":"Palmqvist, S. et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA 324, 772\u2013781 (2020).","journal-title":"JAMA"},{"key":"904_CR20","first-page":"5","volume":"217","author":"N Warmenhoven","year":"2024","unstructured":"Warmenhoven, N. et al. A comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker tests. Brain 217, 5\u20136 (2024).","journal-title":"Brain"},{"key":"904_CR21","doi-asserted-by":"publisher","unstructured":"Barth\u00e9lemy, N. R. et al. Highly accurate blood test for Alzheimer\u2019s disease is similar or superior to clinical cerebrospinal fluid tests. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-024-02869-z (2024).","DOI":"10.1038\/s41591-024-02869-z"},{"key":"904_CR22","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1093\/brain\/awac407","volume":"146","author":"F Gonzalez-Ortiz","year":"2023","unstructured":"Gonzalez-Ortiz, F. et al. Brain-derived tau: a novel blood-based biomarker for Alzheimer\u2019s disease-type neurodegeneration. Brain 146, 1152\u20131165 (2023).","journal-title":"Brain"},{"key":"904_CR23","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.jalz.2018.09.010","volume":"15","author":"Z Chen","year":"2019","unstructured":"Chen, Z. et al. Learnings about the complexity of extracellular tau aid development of a blood-based screen for Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 15, 487\u2013496 (2019).","journal-title":"Alzheimer\u2019s Dement."},{"key":"904_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-024-47286-5","volume":"15","author":"F Gonzalez-Ortiz","year":"2024","unstructured":"Gonzalez-Ortiz, F. et al. Plasma brain-derived tau is an amyloid-associated neurodegeneration biomarker in Alzheimer\u2019s disease. Nat. Commun. 15, 1\u201313 (2024).","journal-title":"Nat. Commun."},{"key":"904_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19543-w","volume":"11","author":"JP Chhatwal","year":"2020","unstructured":"Chhatwal, J. P. et al. Plasma N-terminal tau fragment levels predict future cognitive decline and neurodegeneration in healthy elderly individuals. Nat. Commun. 11, 6024 (2020).","journal-title":"Nat. Commun."},{"key":"904_CR26","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13195-024-01458-z","volume":"16","author":"Z Liu","year":"2024","unstructured":"Liu, Z. et al. Pathophysiology characterization of Alzheimer\u2019s disease in South China\u2019s aging population: for the Greater-Bay-Area Healthy Aging Brain Study (GHABS). Alzheimer\u2019s Res. Ther. 16, 84 (2024).","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"904_CR27","first-page":"1797","volume":"28","author":"M Mil\u00e0-Alom\u00e0","year":"2022","unstructured":"Mil\u00e0-Alom\u00e0, M. et al. Plasma p-tau231 and p-tau217 as state markers of amyloid-\u03b2 pathology in preclinical Alzheimer\u2019s disease. Nat. Med. 28, 1797\u20131801 (2022).","journal-title":"Nat. Med."},{"key":"904_CR28","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s00401-021-02275-6","volume":"141","author":"NJ Ashton","year":"2021","unstructured":"Ashton, N. J. et al. Plasma p-tau231: a new biomarker for incipient Alzheimer\u2019s disease pathology. Acta Neuropathol. 141, 709\u2013724 (2021).","journal-title":"Acta Neuropathol."},{"key":"904_CR29","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1038\/s41591-022-02074-w","volume":"28","author":"NJ Ashton","year":"2022","unstructured":"Ashton, N. J. et al. Differential roles of A\u03b242\/40, p-tau231 and p-tau217 for Alzheimer\u2019s trial selection and disease monitoring. Nat. Med. 28, 2555\u20132562 (2022).","journal-title":"Nat. Med."},{"key":"904_CR30","doi-asserted-by":"publisher","first-page":"3827","DOI":"10.1002\/alz.13803","volume":"20","author":"DP Molina\u2010Henry","year":"2024","unstructured":"Molina\u2010Henry, D. P. et al. Racial and ethnic differences in plasma biomarker eligibility for a preclinical Alzheimer\u2019s disease trial. Alzheimer\u2019s Dement. 20, 3827\u20133838 (2024).","journal-title":"Alzheimer\u2019s Dement."},{"key":"904_CR31","doi-asserted-by":"publisher","first-page":"102507","DOI":"10.1016\/j.arr.2024.102507","volume":"101","author":"WE Wang","year":"2024","unstructured":"Wang, W. E. et al. Neuroimaging and biofluid biomarkers across race and ethnicity in older adults across the spectrum of cognition. Ageing Res. Rev. 101, 102507 (2024).","journal-title":"Ageing Res. Rev."},{"key":"904_CR32","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13024-023-00689-2","volume":"19","author":"J Therriault","year":"2024","unstructured":"Therriault, J. et al. Comparison of immunoassay- with mass spectrometry-derived p-tau quantification for the detection of Alzheimer\u2019s disease pathology. Mol. Neurodegener. 19, 2 (2024).","journal-title":"Mol. Neurodegener."},{"key":"904_CR33","doi-asserted-by":"publisher","first-page":"831","DOI":"10.14283\/jpad.2024.124","volume":"11","author":"D Molina-Henry","year":"2024","unstructured":"Molina-Henry, D. et al. Relationship between plasma p-tau217 and amyloid PET in racial and ethnic underrepresented groups (RE-URG) compared with non RE-URG in LEARN and A4. J. Prev. Alzheimer\u2019s Dis. 11, 831\u2013837 (2024).","journal-title":"J. Prev. Alzheimer\u2019s Dis."},{"key":"904_CR34","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/s43587-023-00405-1","volume":"3","author":"L Montoliu-Gaya","year":"2023","unstructured":"Montoliu-Gaya, L. et al. Mass spectrometric simultaneous quantification of tau species in plasma shows differential associations with amyloid and tau pathologies. Nat. Aging 3, 661\u2013669 (2023).","journal-title":"Nat. Aging"},{"key":"904_CR35","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202114022","author":"N Mattsson-Carlgren","year":"2021","unstructured":"Mattsson-Carlgren, N. et al. Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau. EMBO Mol. Med. https:\/\/doi.org\/10.15252\/emmm.202114022 (2021).","journal-title":"EMBO Mol. Med."},{"key":"904_CR36","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.neuron.2018.02.015","volume":"97","author":"C Sato","year":"2018","unstructured":"Sato, C. et al. Tau kinetics in neurons and the human central nervous system. Neuron 97, 1284\u20131298.e7 (2018).","journal-title":"Neuron"},{"key":"904_CR37","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1001\/jamaneurol.2022.4485","volume":"80","author":"J Therriault","year":"2023","unstructured":"Therriault, J. et al. Association of phosphorylated tau biomarkers with amyloid positron emission tomography vs tau positron emission tomography. JAMA Neurol. 80, 188\u2013199 (2023).","journal-title":"JAMA Neurol."},{"key":"904_CR38","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1038\/s41591-023-02443-z","volume":"29","author":"K Horie","year":"2023","unstructured":"Horie, K. et al. CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer\u2019s disease. Nat. Med. 29, 1954\u20131963 (2023).","journal-title":"Nat. Med."},{"key":"904_CR39","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1002\/alz.13454","volume":"20","author":"R Saloner","year":"2024","unstructured":"Saloner, R. et al. Plasma phosphorylated tau-217 exhibits sex-specific prognostication of cognitive decline and brain atrophy in cognitively unimpaired adults. Alzheimer\u2019s Dement. 20, 376\u2013387 (2024).","journal-title":"Alzheimer\u2019s Dement."},{"key":"904_CR40","doi-asserted-by":"publisher","first-page":"2834","DOI":"10.1093\/brain\/awab481","volume":"145","author":"A Snellman","year":"2022","unstructured":"Snellman, A. et al. N-terminal and mid-region tau fragments as fluid biomarkers in neurological diseases. Brain 145, 2834\u20132848 (2022).","journal-title":"Brain"},{"key":"904_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/alz.14550","volume":"21","author":"G Lan","year":"2025","unstructured":"Lan, G. et al. Plasma N-terminal tau fragment is an amyloid-dependent biomarker in Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 21, 1\u201314 (2025).","journal-title":"Alzheimer\u2019s Dement."},{"key":"904_CR42","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1001\/jamaneurol.2023.5319","volume":"81","author":"NJ Ashton","year":"2024","unstructured":"Ashton, N. J. et al. Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer disease pathology. JAMA Neurol. 81, 255\u2013263 (2024).","journal-title":"JAMA Neurol."},{"key":"904_CR43","doi-asserted-by":"publisher","unstructured":"Du, L. et al. Longitudinal plasma phosphorylated-tau217 and other related biomarkers in a non-demented Alzheimer\u2019s risk-enhanced sample. Alzheimer\u2019s Dement. https:\/\/doi.org\/10.1002\/alz.14100 (2024).","DOI":"10.1002\/alz.14100"},{"key":"904_CR44","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1001\/jamaneurol.2021.5216","volume":"79","author":"WJ Jansen","year":"2022","unstructured":"Jansen, W. J. et al. Prevalence estimates of amyloid abnormality across the Alzheimer disease clinical spectrum. JAMA Neurol. 79, 228\u2013243 (2022).","journal-title":"JAMA Neurol."},{"key":"904_CR45","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","volume":"384","author":"MA Mintun","year":"2021","unstructured":"Mintun, M. A. et al. Donanemab in early Alzheimer\u2019s disease. N. Engl. J. Med. 384, 1691\u20131704 (2021).","journal-title":"N. Engl. J. Med."},{"key":"904_CR46","unstructured":"Lilly\u2019s donanemab significantly slowed cognitive and functional decline in phase 3 study of early Alzheimer\u2019s disease. Eli Lilly and Company https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lillys-donanemab-significantly-slowed-cognitive-and-functional (2023)."},{"key":"904_CR47","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1001\/jamaneurol.2023.0199","volume":"80","author":"S Janelidze","year":"2023","unstructured":"Janelidze, S., Barth\u00e9lemy, N. R., He, Y., Bateman, R. J. & Hansson, O. Mitigating the associations of kidney dysfunction with blood biomarkers of Alzheimer disease by using phosphorylated tau to total tau ratios. JAMA Neurol. 80, 516\u2013522 (2023).","journal-title":"JAMA Neurol."},{"key":"904_CR48","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1186\/s13195-024-01630-5","volume":"16","author":"AL Wojda\u0142a","year":"2024","unstructured":"Wojda\u0142a, A. L. et al. Analytical and clinical performance of eight Simoa\u00ae and Lumipulse\u00ae assays for automated measurement of plasma p-tau181 and p-tau217. Alzheimer\u2019s Res. Ther. 16, 266 (2024).","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"904_CR49","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1002\/alz.12236","volume":"17","author":"TK Karikari","year":"2021","unstructured":"Karikari, T. K. et al. Head-to-head comparison of clinical performance of CSF phospho-tau T181 and T217 biomarkers for Alzheimer\u2019s disease diagnosis. Alzheimer\u2019s Dement. 17, 755\u2013767 (2021).","journal-title":"Alzheimer\u2019s Dement."},{"key":"904_CR50","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/s41582-024-00977-5","volume":"20","author":"SE Schindler","year":"2024","unstructured":"Schindler, S. E. et al. Acceptable performance of blood biomarker tests of amyloid pathology-recommendations from the Global CEO Initiative on Alzheimer\u2019s Disease. Nat. Rev. Neurol. 20, 426\u2013439 (2024).","journal-title":"Nat. Rev. Neurol."},{"key":"904_CR51","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1038\/s43587-023-00471-5","volume":"3","author":"WS Brum","year":"2023","unstructured":"Brum, W. S. et al. A two-step workflow based on plasma p-tau217 to screen for amyloid \u03b2 positivity with further confirmatory testing only in uncertain cases. Nat. Aging 3, 1079\u20131090 (2023).","journal-title":"Nat. Aging"},{"key":"904_CR52","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1001\/jamaneurol.2023.4596","volume":"81","author":"N Mattsson-Carlgren","year":"2024","unstructured":"Mattsson-Carlgren, N. et al. Plasma biomarker strategy for selecting patients with Alzheimer disease for antiamyloid immunotherapies. JAMA Neurol. 81, 69\u201378 (2024).","journal-title":"JAMA Neurol."},{"key":"904_CR53","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s00401-023-02659-w","volume":"147","author":"J Lantero-Rodriguez","year":"2024","unstructured":"Lantero-Rodriguez, J. et al. CSF p-tau205: a biomarker of tau pathology in Alzheimer\u2019s disease. Acta Neuropathol. 147, 12 (2024).","journal-title":"Acta Neuropathol."},{"key":"904_CR54","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1212\/WNL.0b013e3181cb3e25","volume":"74","author":"RC Petersen","year":"2010","unstructured":"Petersen, R. C. et al. Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology 74, 201\u2013209 (2010).","journal-title":"Neurology"},{"key":"904_CR55","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.jalz.2016.10.006","volume":"13","author":"M Weiner","year":"2017","unstructured":"Weiner, M. et al. The Alzheimer's Disease Neuroimaging Initiative 3: continued innovation for clinical trial improvement. Alzheimer's Dement 13, 561\u2013571 (2017).","journal-title":"Alzheimer's Dement"},{"key":"904_CR56","doi-asserted-by":"publisher","first-page":"571","DOI":"10.14283\/jpad.2023.49","volume":"10","author":"L Cui","year":"2023","unstructured":"Cui, L. et al. Chinese Preclinical Alzheimer\u2019s Disease Study (C-PAS): design and challenge from PET acceptance. J. Prev. Alzheimer\u2019s Dis. 10, 571\u2013580 (2023).","journal-title":"J. Prev. Alzheimer\u2019s Dis."},{"key":"904_CR57","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1007\/s00259-024-06862-z","volume":"52","author":"B Li","year":"2024","unstructured":"Li, B. et al. Loss of synaptic density in nucleus basalis of meynert indicates distinct neurodegeneration in Alzheimer\u2019s disease: the RJNB-D study. Eur. J. Nucl. Med. Mol. Imaging 52, 134\u2013144 (2024).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"904_CR58","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1097\/JGP.0b013e31819431d5","volume":"17","author":"AJ Jak","year":"2009","unstructured":"Jak, A. J. et al. Quantification of five neuropsychological approaches to defining mild cognitive impairment. Am. J. Geriatr. Psychiatry 17, 368\u2013375 (2009).","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"904_CR59","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1002\/alz.13525","volume":"20","author":"F Gonzalez-Ortiz","year":"2024","unstructured":"Gonzalez-Ortiz, F. et al. A novel ultrasensitive assay for plasma p-tau217: performance in individuals with subjective cognitive decline and early Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 20, 1239\u20131249 (2024).","journal-title":"Alzheimer\u2019s Dement."},{"key":"904_CR60","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1002\/alz.13764","volume":"20","author":"MR Meyer","year":"2024","unstructured":"Meyer, M. R. et al. Clinical validation of the PrecivityAD2 blood test: a mass spectrometry-based test with algorithm combining %p-tau217 and A\u03b242\/40 ratio to identify presence of brain amyloid. Alzheimer\u2019s Dement. 20, 3179\u20133192 (2024).","journal-title":"Alzheimer\u2019s Dement."},{"key":"904_CR61","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.neuroimage.2006.01.021","volume":"31","author":"RS Desikan","year":"2006","unstructured":"Desikan, R. S. et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. NeuroImage 31, 968\u2013980 (2006).","journal-title":"NeuroImage"},{"key":"904_CR62","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1002\/ana.26492","volume":"92","author":"G Lan","year":"2022","unstructured":"Lan, G. et al. Association of presynaptic loss with Alzheimer\u2019s disease and cognitive decline. Ann. Neurol. 92, 1001\u20131015 (2022).","journal-title":"Ann. Neurol."},{"key":"904_CR63","doi-asserted-by":"publisher","first-page":"567","DOI":"10.2967\/jnumed.114.148981","volume":"56","author":"SM Landau","year":"2015","unstructured":"Landau, S. M. et al. Measurement of longitudinal \u03b2-amyloid change with 18F-florbetapir PET and standardized uptake value ratios. J. Nucl. Med. 56, 567\u2013574 (2015).","journal-title":"J. Nucl. Med."},{"key":"904_CR64","doi-asserted-by":"publisher","unstructured":"Li, A. et al. [18F]-D3FSP \u03b2-amyloid PET imaging in older adults and Alzheimer\u2019s disease. Eur. J. Nucl. Med. Mol. Imaging https:\/\/doi.org\/10.1007\/s00259-024-06835-2 (2024).","DOI":"10.1007\/s00259-024-06835-2"},{"key":"904_CR65","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1002\/ana.26885","volume":"95","author":"G Lan","year":"2024","unstructured":"Lan, G. et al. Microglial reactivity correlates with presynaptic loss independent of \u03b2-amyloid and tau. Ann. Neurol. 95, 917\u2013928 (2024).","journal-title":"Ann. Neurol."},{"key":"904_CR66","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.neuroimage.2017.05.058","volume":"157","author":"A Maass","year":"2017","unstructured":"Maass, A. et al. Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer\u2019s disease. NeuroImage 157, 448\u2013463 (2017).","journal-title":"NeuroImage"},{"key":"904_CR67","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13195-020-00665-8","volume":"12","author":"T Guo","year":"2020","unstructured":"Guo, T. et al. Normalization of CSF pTau measurement by A\u03b240 improves its performance as a biomarker of Alzheimer\u2019s disease. Alzheimer\u2019s Res. Ther. 12, 97 (2020).","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"904_CR68","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1002\/alz.12890","volume":"19","author":"G Lan","year":"2023","unstructured":"Lan, G., Li, A., Liu, Z., Ma, S. & Guo, T. Presynaptic membrane protein dysfunction occurs prior to neurodegeneration and predicts faster cognitive decline. Alzheimer\u2019s Dement. 19, 2408\u20132419 (2023).","journal-title":"Alzheimer\u2019s Dement."},{"key":"904_CR69","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jalz.2018.09.001","volume":"15","author":"R La Joie","year":"2019","unstructured":"La Joie, R. et al. Multisite study of the relationships between antemortem [11C]PIB-PET Centiloid values and postmortem measures of Alzheimer\u2019s disease neuropathology. Alzheimer\u2019s Dement. 15, 205\u2013216 (2019).","journal-title":"Alzheimer\u2019s Dement."},{"key":"904_CR70","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-019-0478-z","author":"G Salvad\u00f3","year":"2019","unstructured":"Salvad\u00f3, G. et al. Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers. Alzheimer\u2019s Res. Ther. https:\/\/doi.org\/10.1186\/s13195-019-0478-z (2019).","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"904_CR71","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.neuron.2016.01.028","volume":"89","author":"M Sch\u00f6ll","year":"2016","unstructured":"Sch\u00f6ll, M. et al. PET imaging of tau deposition in the aging human brain. Neuron 89, 971\u2013982 (2016).","journal-title":"Neuron"},{"key":"904_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v098.i11","volume":"98","author":"C Thiele","year":"2021","unstructured":"Thiele, C. & Hirschfeld, G. cutpointr: improved estimation and validation of optimal cutpoints in R. J. Stat. Softw. 98, 1\u201327 (2021).","journal-title":"J. Stat. Softw."},{"key":"904_CR73","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/1471-2105-12-77","volume":"12","author":"X Robin","year":"2011","unstructured":"Robin, X. et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics 12, 77 (2011).","journal-title":"BMC Bioinformatics"}],"container-title":["Nature Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43587-025-00904-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43587-025-00904-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43587-025-00904-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T22:10:13Z","timestamp":1757196613000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43587-025-00904-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,23]]},"references-count":73,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["904"],"URL":"https:\/\/doi.org\/10.1038\/s43587-025-00904-3","relation":{},"ISSN":["2662-8465"],"issn-type":[{"value":"2662-8465","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,23]]},"assertion":[{"value":"20 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}